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restoration based on appropriate criteria. Third, the studies had to state or use criteria for deciding when a restoration had failed and needed to be replaced. However, such strict inclusion criteria were then relaxed as no study which met them was identified. The final studies included in the review were all case series. Details of sample sizes, follow-up and key results were provided separately for each of the included studies.
Sources searched to identify primary studies
MEDLINE, EMBASE, and the Cochrane Library were searched from 1966 to June 2003 using the keywords "inlays", "life tables" (or "lifetables"), and "Kaplan-Meier" (or "KaplanMeier"). A handsearch of studies included in a recently published systematic review was also performed.
Criteria used to ensure the validity of primary studies
The validity of primary studies was, in principle, ensured by the inclusion criteria used in the review. However, some inclusion criteria had to be relaxed because of the lack of randomised studies, and only case series were used. The internal validity of these studies appears to have been low.
Methods used to judge relevance and validity, and for extracting data
Not stated.
Number of primary studies included
Four studies were identified using the basic inclusion criteria, while 6 studies were identified through the handsearch. Thus, in total, 10 studies provided data.
Methods of combining primary studies
A meta-analysis was used to pool the annual survival rates from different studies. Each study was weighted by the inverse of the variance (one divided by the square of the standard error) of the effect estimate.
Investigation of differences between primary studies
The studies were characterised by different follow-up periods, which ranged from 3 to 20 years.
Results of the review
The survival rate decreased from 0.973 at year 1 to 0.909 at year 9 for laboratory-fabricated ceramic inlays, from 0.996 at year 1 to 0.891 at year 9 for chairside CAD/CAM ceramic inlays, and from 1.000 at year 1 to 0.917 at year 9 for gold inlays.
Measure of benefits used in the economic analysis
The summary benefit measure was inlay longevity. This was measured in terms of the number of failure-free years. An annual discount rate of 3% was applied as the benefits occurred over a long-term period.
